Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Francis Alberta

Sports Medicine Hackensack, NJ Medical Doctor

NPI 1821065863 CMS profile 36766

385 Prospect Avenue, Hackensack, NJ 07601

Open in the dashboard

General payments

$61,292

180 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Francis Alberta of Hackensack, NJ is reported in the CMS Open Payments database as having received $61,292 across 180 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $52,983 86
2024 General $1,708 30
2023 General $824 14
2022 General $890 23
2021 General $3,043 19
2020 General $66 3
2019 General $1,777 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Francis Alberta
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Francis Alberta were reported at $52,983. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Francis Alberta Sports Medicine median Middle half National median
2019 $1,777 $1,176 $199–$4,249 $163
2020 $66 $708 $96–$2,890 $114
2021 $3,043 $1,213 $152–$3,994 $132
2022 $890 $1,230 $159–$3,998 $149
2023 $824 $584 $146–$2,836 $160
2024 $1,708 $628 $163–$3,168 $164
2025 $52,983 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Encore Medical, LP $26,881 6 payments
  2. Zimmer Biomet Holdings, Inc. $26,072 47 payments
  3. Arthrex, Inc. $2,203 6 payments
  4. SeaPearl Inc $1,744 41 payments
  5. Integra LifeSciences Corporation $1,681 4 payments
  6. Globus Medical, Inc. $541 12 payments
  7. GlaxoSmithKline, LLC. $449 30 payments
  8. DePuy Synthes Sales Inc. $331 8 payments
  9. Catalyst OrthoScience $296 2 payments
  10. Linvatec Corporation $142 1 payment
  11. Other $951 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $47,984 9 payments
  2. Food and Beverage $6,613 150 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,000 3 payments
  4. Travel and Lodging $2,158 15 payments
  5. Education $538 3 payments
Products named General payments · program years 2019–2025
  1. DJO SURGICAL $26,523 3 payments
  2. FREEDOM WRIST $1,640 3 payments
  3. TITAN-SHOULDER $1,640 3 payments
  4. EXTERNAL FIXATION SYSTEM $1,640 3 payments
  5. REVERSE SHOULDER $1,500 1 payment
  6. NUCALA $449 30 payments
  7. Comprehensive Shoulder System $316 4 payments
  8. Osseofit $279 1 payment
  9. ANTHEM $273 7 payments
  10. Identity $259 2 payments
  11. Other $3,983 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

161

Median for Orthopedic Surgery: 203

Drug cost

$696

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Meloxicam Generic 76 $313
Diclofenac Sodium Generic 15 $147
Methylprednisolone Generic 13 $84
Tramadol Hcl Generic 23 $66
Cyclobenzaprine Hcl Generic 11 $64
Amoxicillin Generic 23 $23

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$275,636

Of which drugs: $713

Medicare patients

520

Average age 74

Services billed

4,294

300 women, 220 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 33%
Diabetes 27%
Osteoporosis 22%
Depression 19%
Cancer 14%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 108 954 $699
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 100 1,521 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $96
$96 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

180 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record